Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway 1,2 . For the 50% of patients with histiocytosis who have BRAF V600 mutations 3-5 , RAF inhibition is highly efficacious and has markedly altered the natural history of the disease 6,7 . However, no standard therapy exists for the remaining 50% of patients who lack BRAF V600 mutations. Although ERK dependence has been hypothesized to be a consistent feature across histiocytic neoplasms, this remains clinically unproven and many of the kinase mutations that are found in patients who lack BRAF V600 mutations have not previously been biologically characterized. Here we show ERK dependency in histiocytoses through a proof-of-concept clinical trial of cobimetinib, an oral inhibitor of MEK1 and MEK2, in patients with histiocytoses. Patients were enrolled regardless of their tumour genotype. In parallel, MAPK alterations that were identified in treated patients were characterized for their ability to activate ERK. In the 18 patients that we treated, the overall response rate was 89% (90% confidence interval of 73-100). Responses were durable, with no acquired resistance to date. At one year, 100% of responses were ongoing and 94% of patients remained progressionfree. Cobimetinib treatment was efficacious regardless of genotype, and responses were observed in patients with ARAF, BRAF, RAF1, NRAS, KRAS, MEK1 (also known as MAP2K1) and MEK2 (also known as MAP2K2) mutations. Consistent with the observed responses, the characterization of the mutations that we identified in these patients confirmed that the MAPK-pathway mutations were activating. Collectively, these data demonstrate that histiocytic neoplasms are characterized by a notable dependence on MAPK signalling-and that they are consequently responsive to MEK inhibition. These results extend the benefits of molecularly targeted therapy to the entire spectrum of patients with histiocytosis.
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On the basis of the success of targeting BRAF V600 in two histiocytic neoplasms (Erdheim-Chester disease and Langerhans cell histiocytosis), we and others attempted to identify potential genomic drivers of disease in patients that do not possess this mutation. These genomic studies of histiocytoses have identified a considerable diversity of both previously characterized and newly identified alterations that involve multiple components of the MAPK pathway [8] [9] [10] [11] [12] [13] . Many of the recurrent mutations in histiocytic neoplasms occur in genes for MAPKpathway proteins-such as ARAF, RAF1, MEK1 and MEK2-that are rarely, if ever, mutated in other malignancies. Consequently, many of these mutations have not previously been biologically characterized. Consistent with the underlying hypothesis that these non-BRAF V600 mutations are likely to drive histiocytic neoplasms, drugs that inhibit both the MEK1 and MEK2 kinases, which are immediately downstream of BRAF, have previously been shown in case reports to evoke responses in patients with non-BRAF V600 mutations [14] [15] [16] . Despite these findings, the true extent and durability of these responses, as well as the safety of MEK1 and MEK2 inhibition across a wide range of histologic and molecular subsets of histiocytosis, remains unknown.
To formally evaluate the therapeutic potential of MEK1 and MEK2 inhibition in histiocytic neoplasms, we conducted a phase II study of cobimetinib in adult patients with histiocytoses of any mutational status (clinicaltrials.gov identifier NCT01953926). Consistent with common clinical practice for response assessment in these disorders [17] [18] [19] , the primary end point was response rate (complete response + partial response) as determined by fluorodeoxyglucose positron emission tomography (PET). To provide additional corroboration of treatment efficacy, a key secondary end point included the response by computed tomography and/or magnetic resonance imaging (MRI), according to the 'Response Evaluation Criteria in Solid Tumours' (RECIST) version 1.1 20 . Simultaneously, we used this clinical trial as a platform to perform real-time, patient-driven discovery of MAPK-pathway alterations through biological characterization of the alterations that were identified by comprehensive profiling of patient samples.
We enrolled and treated a total of 18 patients (Extended Data  Table 1) , who had a variety of histiocytic neoplasms that included Erdheim-Chester disease (n = 12 patients), Langerhans cell histiocytosis (n = 2), Rosai-Dorfman disease (n = 2) and mixed histiocytosis (n = 2). Eighty-nine per cent (16 out of 18) of patients had received at least 1 previous therapy and 56% (10 out of 18) had received 2 or more previous therapies. Five patients (28%) had an Eastern Cooperative Oncology Group performance status of ≥2.
At the time of the pre-planned primary efficacy analysis, which was performed using a data cut-off of 25 April 2018, the overall response rate was 89% (90% one-sided confidence interval of 73-100) as determined by the PET response criteria (Fig. 1a) . Overall, 72% of the patients (13 out of 18) had a complete response, 17% (3 out of 18) had a partial response, 6% (1 out of 18) experienced stable disease, none had progressive disease and 6% (1 out of 18) could not be evaluated owing to early withdrawal for clinical deterioration (Extended Data Table 2 ). All patients, including the patient who could not be evaluated, were accounted for in our analysis, according to the protocol. The patient who could not be evaluated was counted as not responding to treatment. Responses occurred at all sites of disease, including the central nervous system-a site that is associated with higher morbidity and mortality 21 . According to RECIST version 1.1 (judged on the basis of computed tomography and/or MRI), the overall response rate was 64% (90% onesided confidence interval of 44-100) in the 14 out of 18 patients who Letter reSeArCH were evaluable by these criteria (Extended Data Fig. 1 ). The median time to best response, according to PET response criteria, was 3.2 months (range of 1.6-15.9 months, Fig. 1b) . At the time of data analysis, 50% (9 out of 18) of patients remained on protocol therapy and an additional 17% (3 out of 18)-all in the complete-response categoryhad elected to withdraw and continue to receive MEK inhibitory therapy off-label.
The median duration of response and the median progression-free survival had not yet been reached after a median follow-up of 11.9 months (range of 4.6-26.4 months) (Fig. 1c, Extended Data Fig. 2) . No responding patient has progressed to date. Among those who discontinued treatment for any reason, the median time on treatment was 11.9 months (range of 1.6-23.7 months). At one year, 100% of responses were ongoing and 94% of patients remained progression-free.
The adverse events observed are shown in Extended Data Tables 3, 4 . Overall, the safety profile was consistent with previous studies of cobimetinib 22, 23 . Of the 18 treated patients, 10 (56%) had their cobimetinib dose reduced at least once. Adverse events leading to dose reduction included ejection-fraction decrease in five patients, rash in two patients, diarrhoea in two patients, and fatigue and thrombocytopenia (each in one patient). In all cases, patients who had their doses reduced had their best response maintained at the lower dose. One patient permanently discontinued cobimetinib owing to an adverse event (central retinal vein occlusion). Another patient with extensive baseline histiocytic lung involvement died of pneumonia-deemed to be unrelated to the treatment with cobimetinib-before the first assessment of response.
To identify the MAPK-pathway alterations that were present in each patient, we performed a variety of sequencing assays according to tissue availability (Extended Data Table 5 ). In some cases, MAPK mutations were defined on the basis of sequencing that was performed at an external commercial laboratory. At least one mutation that involved the MAPK pathway was identified in 83% (15 out of 18) of patients. Patients had a variety of MAPK-pathway mutations involving BRAF (n = 5 with BRAF
V600
, n = 1 with non-V600 BRAF), MEK1 (n = 4), KRAS (n = 3), ARAF (n = 2), RAF1 (n = 1), MEK2 (n = 1) and NRAS (n = 1). Two patients had mutations that involved more than one gene in the MAPK pathway. Three patients had an unknown mutational status, including one case in which sequencing of two separate biopsies failed owing to low tumour cellularity. Responses to cobimetinib were observed across genotypes, as well as in two of the three patients with unknown mutations (Fig. 1a) . Although several alterations detected here (including several in BRAF, ARAF and MEK1) are known to be recurrent in histiocytoses, RAF1 mutations have not previously been described in histiocytoses, and the specific RAF1, MEK2 and BRAF mutations that we identify here have not, to our knowledge, been functionally characterized in any setting (Extended Data Fig. 3 ). We therefore evaluated the transforming potential, ability to activate ERK and responsiveness to cobimetinib in vitro for each of these three mutations. In each case, introducing the MEK2
Y134H
, BRAF N486_T491delinsK (which leads to a replacement of Asn 486 to Thr 491 with a single lysine residue) or RAF1 K106N mutations robustly led to cytokine independence in Ba/F3 cells (a mouse IL-3-dependent, pro-B cell line) and activated ERK signalling, whereas wild-type MEK2, RAF1 and BRAF did not ( Fig. 2a-f) . Moreover, the expression of each mutation sensitized Ba/F3 cells to cobimetinib, whereas parental Ba/F3 cells remain relatively insensitive to cobimetinib (Fig. 2g ). These in vitro responses were consistent with the clinical responses that were seen in the trial in patients who bear these same alleles (Fig. 1a, b , 2a, c, e).
In this study, the selective inhibitor of MEK1 and MEK2 cobimetinib had marked and durable activity in adults with histiocytic neoplasms. Responses to cobimetinib were observed across histiocytosis subtypes and tumour genotypes, although-consistent with the expectations for a study that mandated adult patients with either refractory or multi-organ disease-the majority (67%) of patients we treated had Erdheim-Chester disease. Therefore, some caution is warranted when applying these findings to all patients with histiocytosis. The efficacy of cobimetinib across MAPK genotypes here is notable given that the single-agent efficacy of MEK1 and MEK2 inhibitors in other solid tumours with alterations to the MAPK pathway has generally been disappointing 24 . Indeed, previous work has shown that RAS mutations vary in their dependence on MEK1 and MEK2 25, 26 . Similarly, preclinical studies have previously suggested that several MEK1 and MEK2 mutations, including some that were observed in the patients we treated, would confer resistance to MEK1 and MEK2 inhibition 27, 28 . Importantly, responses to cobimetinib were not only nearly universal but also durable; in fact, no acquired resistance has been observed to date. This finding suggests that histiocytic neoplasms may lack the ability to adapt to tonic MEK1 and MEK2 inhibition, and that cobimetinib may markedly alter the natural history of these disorders. It is noteworthy that a similar efficacy and durability of response has previously been observed with vemurafenib in the subset of histiocytic neoplasms that contain BRAF V600 mutations 6, 7 . Overall, our data demonstrate that treatment with cobimetinib results in consistent and durable responses across clinical and genetic subtypes of histiocytic neoplasms, which represents an area of Letter reSeArCH previously unmet medical need. These findings further suggest that histiocytic neoplasms are collectively characterized by dependence on MAPK-pathway signalling and, consequently, are responsive to the inhibition of MEK1 and MEK2.
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MEthodS
The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Patients. Eligible patients had a histiocytic neoplasm, were aged 16 or older, had an Eastern Cooperative Oncology Group performance-status score of 0 to 3 (on a scale from 0 to 5, with higher scores indicating greater disability) and had adequate major organ function. Patients were required to have one of the following: (1) multi-system disease; (2) disease that was recurrent or refractory to standard therapies; or (3) single-organ system disease that was deemed unlikely to benefit from conventional therapies (for example, central nervous system or cardiac involvement). Patients with tumours that were wild type for BRAF V600 were eligible. Patients with BRAF V600 mutations were eligible only in the setting of (1) intolerance or resistance to previous BRAF inhibitor therapy or (2) the inability to access BRAF inhibitor therapy. Complete eligibility criteria are available in the study protocol (see Supplementary Information) .
The protocol was approved by the institutional review board at Memorial Sloan Kettering Cancer Center, complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines and the Declaration of Helsinki. All patients provided written informed consent. Study design and treatment. The primary end point was the overall response rate (complete responses + partial responses) by PET response criteria (see Supplementary Information). These criteria were previously used for analysis of vemurafenib efficacy in BRAF V600 -mutant histiocytic disorders, a dataset that formed the basis of regulatory authorization for this indication in the United States
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. PET responses were investigator-assessed by a radiologist with dual board certification in diagnostic radiology and nuclear medicine (G.A.U.). Secondary end points included the duration of response and progression-free survival based on PET criteria, safety and overall response rate according to RECIST version 1.1. Patients received cobimetinib at a starting dose of 60 mg daily for 21 days of each 28-day cycle. Study assessments. Tumour assessments were performed by means of PET and computed tomography, MRI or clinical measurement with calipers (in the case of cutaneous lesions) at baseline, every 8 weeks for 6 months and every 16 weeks thereafter until disease progression. Adverse events were assessed from the date that informed consent was obtained until at least 28 days after the final dose of cobimetinib was administered. Adverse events were classified and graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (https:// evs.nci.nih.gov/ftp1/CTCAE/About.html). Study oversight. Data, safety and quality monitoring were performed by the Memorial Sloan Kettering Cancer Center Data and Safety Monitoring Committee. All data elements were de-identified by removing identifying characteristics and replacing them with code numbers 1 through 18. Statistical analysis. All the analyses were conducted in accordance with the pre-specified statistical plan as outlined in the protocol, unless otherwise indicated (see Supplementary Information) . The primary analysis presented here was performed at the time the first 18 consecutively enrolled patients to receive cobimetinib were evaluable for response, or discontinued protocol therapy (Extended Data Fig. 4) . Patients who discontinued therapy without a post-baseline tumour assessment were considered to be non-responsive to treatment. Assuming a binary end point of PET response (complete response or partial response, versus neither), we estimated that a sample of 18 patients would provide the study with 90% power to test the hypothesis that the response rate is promising (defined as 35% or higher) against a non-promising rate of 10% or lower. Using an exact, one-sample test for binomial proportion-with type I error = 10% and type II error = 10%-the above rates provided a sample size of 18 patients; if at least 4 out of 18 responses were observed then this would be considered a positive study (that is, conclude that the true response rate is above 10%). Ruling out a lower limit of 10% for the overall response rate was considered to be clinically meaningful in light of the poor response to treatment in the context of multi-system or refractory histiocytosis. Secondary end points included overall response rate according to RECIST version 1.1, and duration of response and progression-free survival based on PET criteria, as estimated by the Kaplan-Meier method. Duration of response was defined as beginning with the date of response and ending with the date of progression, the beginning of an alternative anti-cancer (non-MEK inhibitor) therapy, death or the date of final follow-up. Progression-free survival was defined as the time from the first day of study treatment until the first documented progression of disease or death from any cause (whichever occurred first), or the date of the final follow-up. Patients who discontinued cobimetinib (in the absence of progression) to receive an off-label MEK inhibitor were censored for duration of response and progression-free survival at the final follow-up date. These patients were also considered to be continuing treatment for the purposes of calculating treatment-duration exposure. Fluorodeoxyglucose PET and RECIST responses were investigatorassessed. All patients who received at least one dose of cobimetinib were included in both the efficacy and safety analysis set. All statistical analyses were performed with R, version 3.5.0 (http://www.R-project.org/) Genomic analysis. For patients with samples that were available for centralized testing, genomic analyses for MAPK-pathway mutations were performed on DNA extracted from histiocyte tissue biopsies using a variety of assays-most commonly, targeted exon sequencing using MSK-IMPACT or Heme-PACT 29, 30 . Targeted RNA sequencing was also used for the purposes of detecting gene fusions using the Archer FusionPlex Custom Solid Panel 31 . Whole-exome sequencing was also performed, based on DNA adequacy, using fingernails as a germline control according to previously described methods 8 . In some cases, different biopsies from the same individual were used for different genomic assays. Histiocytic neoplasms are routinely characterized by low tumour cellularity, which often results in low variant-allele fractions even for well-established driver mutations such as BRAF V600 (ref. Membranes were blocked for 1 h at room temperature in 5% bovine serum albumin (BSA) in TBST before being incubated overnight at 4 °C with the primary antibodies. All primary antibodies were diluted 1:1,000 in 5% BSA in TBST, except anti-β-actin, which was diluted 1:5,000 in 5% BSA in TBST. After three washes of 10 min in TBST, secondary antibodies were diluted 1:2,000 in 5% BSA in TBST and incubated for 1 h at room temperature. After another three washes in TBST, detection of the signal was achieved by incubating the membrane on an ECL solution from Millipore and exposure on autoradiography films from Denville Scientific. Drug studies. Cobimetinib was purchased from Selleckchem. Drug studies were conducted in vitro using fluorescence-activated cell-sorted, DAPI − eGFP + Ba/F3 cells that stably expressed the MIGII-empty vector, MIGII-MEK2(Y134H), MIGII-RAF1(K106N) and MIGII-BRAF(N486_T491delinsK) constructs using the CellTiter-Glo Luminescent Cell Viability Assay from Promega Corporation, according to the manufacturer's instructions. The MIGII-MEK2(Y134H), MIGII-RAF1(K106N) and MIGII-BRAF(N486_T491delinsK), fluorescence-activated cell-sorted Ba/F3 cells were maintained in RPMI + 10% FBS + penicillin and streptomycin medium, without mouse IL-3. MIGII-EV was maintained in RPMI + 10% FBS + penicillin and streptomycin with recombinant mouse IL-3 (1 ng/ml). Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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Sample size A sample of 18 patients was estimated to provide the study with 90% power to test the hypothesis that the response rate is promising (defined as 35% or higher) against a non-promising rate of 10% or lower. Using an exact, one-sample test for binomial proportion, with Type I error=10% and Type II error=10%, the above rates provided a sample size of 18 patients; if at least 4/18 responses were observed then this would be considered a positive study (i.e. conclude that the true response rate is >10%). Ruling out a lower limit of 10% for the overall response rate was considered to be clinically meaningful in light of the poor response to treatment in the context of multi-system or refractory histiocytosis.
Data exclusions No data was excluded.
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Clinical data elements were not replicated as it is not possible for a clinical trial. Western blots, growth curves, and Cell titer glows were performed in biological triplicate and were the data were reliably reproduced.
Randomization No randomization was performed.
Blinding
No blinding was performed as this was a single-arm, open-label, non-randomized, phase II clinical trial. The investigators were not blinded to allocation or outcome assessments in the laboratory experiments.
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